Publication | Open Access

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

OncologyPhase IiGastrointestinal OncologyEsophageal CancerMedicinePathologyAmg 386Placebo-controlled StudyCancer TreatmentPharmacologyRadiation Oncology